<?xml version="1.0" encoding="UTF-8"?>
<results title="testTrace">
 <result pre="increasing human-to-human transmission leading to extensive mitigation strategies, including patient" exact="quarantine" post="and mass â€œsocial distancingâ€� measures. Although the clinical manifestation"/>
 <result pre="smoking status; these factors puts them at higher risk of" exact="infection" post="and severe complications arising from CoVID-19. Hence, this review"/>
 <result pre="and S2, which play a pivotal role in mediating viral" exact="infection" post="through binding the host receptor [11,12]. The interaction between"/>
 <result pre="for packaging the viral genome through protein oligomerization. As the" exact="infection" post="progresses, it deleteriously affects the normal activity of most"/>
 <result pre="sneezing and through contact of infected surfaces, then mediating the" exact="infection" post="through the mouth, nose, or eyes [32]. Transmission via"/>
 <result pre="with an immune response or cytokine storm induced by SARS-CoV-2" exact="infection" post="could enhance the infection severity [32]. Since human-to-human transmission"/>
 <result pre="or cytokine storm induced by SARS-CoV-2 infection could enhance the" exact="infection" post="severity [32]. Since human-to-human transmission is the primary mode"/>
 <result pre="toward mitigating CoVID-19 has largely been based on social/physical distancing," exact="isolation" post="of cases, and quarantine measures [25]. Further studies have"/>
 <result pre="largely been based on social/physical distancing, isolation of cases, and" exact="quarantine" post="measures [25]. Further studies have also shown that infectious"/>
 <result pre="of CoVID-19 every seven days since each patient transmitted the" exact="infection" post="to an additional 2.2 individuals. Similarly, other modeling studies"/>
 <result pre="mild cold-like symptoms to severe life-threatening respiratory tract infections. The" exact="infection" post="begins with the gradual onset of symptoms following an"/>
 <result pre="is characterized by mild constitutional symptoms and upper respiratory tract" exact="infection" post="[41]. The most frequently experienced symptoms include fever, dry"/>
 <result pre="and ARDS, which is the most ominous feature of this" exact="infection" post="[29,41,43,46]. Other secondary manifestations, which could be present, are"/>
 <result pre="no specific antiviral drugs or vaccine recommended specifically for SARS-CoV-2" exact="infection" post="for potential therapy of humans till date, scientists are"/>
 <result pre="endeavoring to find drugs to treat this disease. Currently, the" exact="treatment" post="is symptomatic and oxygen therapy is considered as the"/>
 <result pre="is symptomatic and oxygen therapy is considered as the major" exact="treatment" post="intervention for patients with severe infection [41]. Pharmacological interventions"/>
 <result pre="considered as the major treatment intervention for patients with severe" exact="infection" post="[41]. Pharmacological interventions that can prevent a mild state"/>
 <result pre="reactive cytokine production is of crucial importance. Studies are currently" exact="testing" post="the efficacy of existing broad-spectrum antiviral drugs in inhibiting"/>
 <result pre="experimental models [60,61]. Reports show that remdesivir can inhibit CoVID-19" exact="infection" post="efficiently in a human cell line (human liver cancer"/>
 <result pre="have also reported that remdesivir yielded promising results in the" exact="treatment" post="of a patient with CoVID-19 in the U.S. [46],"/>
 <result pre="at both, entry and at post-entry stages of the CoVID-19" exact="infection" post="in Vero E6 cells and has an immune-modulating activity,"/>
 <result pre="RNA viruses [67]. So clinical trials of favipiravir on CoVID-19" exact="infection" post="have now been initiated by the Clinical Medical Research"/>
 <result pre="exploring the efficacy and safety of the drugs in the" exact="treatment" post="of CoVID-19 and the findings need to be validated"/>
 <result pre="that are specifically geared to limit the spread of the" exact="infection" post="from person to person and reduce the number of"/>
 <result pre="widespread mortality of the disease by slowing the rate of" exact="infection" post="to a manageable level that healthcare systems can withhold."/>
 <result pre="a person feels unwell [41]. Whereas, community-based mitigation strategies include," exact="social distancing," post="avoiding crowded areas, and restriction on public gathering and"/>
 <result pre="boost the immune response at the initial stage of CoVID-19" exact="infection" post="might be a prudent approach to overcome the symptoms"/>
 <result pre="a prudent approach to overcome the symptoms associated with this" exact="infection" post="[74]. There has also been evidence that traditional or"/>
 <result pre="light of this evidence, the Chinese government promoted this herbal" exact="treatment" post="to be used in the diagnosis and treatment of"/>
 <result pre="government promoted this herbal treatment to be used in the" exact="diagnosis" post="and treatment of patients who have or are suspected"/>
 <result pre="this herbal treatment to be used in the diagnosis and" exact="treatment" post="of patients who have or are suspected to have"/>
 <result pre="the positive effects of this medicinal plant [78,79,80,81], WHO advised" exact="testing" post="the efficacy and adverse side effects of this plant"/>
 <result pre="to the existing problem among other issues such as late" exact="diagnosis" post="and late antiviral therapy. The limited availability of ICU"/>
 <result pre="viral transmission, engaging in appropriate self-care, following self-hygiene guidelines and" exact="social distancing," post="which are fundamental in avoiding preventable hospitalizations [29]. However,"/>
 <result pre="Novel Coronavirus (COVID-19)Environ. Sci Technol.20205410.1021/acs.est.0c0110232202420 33.WeberD.J.RutalaW.A.FischerW.A.KanamoriH.Sickbert-BennettE.E.Emerging infectious diseases: Focus on" exact="infection" post="control issues for novel coronaviruses (Severe Acute Respiratory Syndrome-CoV"/>
 <result pre="early phase of the outbreakInt. J. Infect. Dis.20209221421710.1016/j.ijid.2020.01.05032007643 40.ZhaiP.DingY.WuX.LongJ.ZhongY.LiY.The epidemiology," exact="diagnosis" post="and treatment of COVID-19Int J. Antimicrob Agents20205510595510.1016/j.ijantimicag.2020.10595532234468 41.CascellaM.RajnikM.CuomoA.DulebohnS.C.Di NapoliR.Features,"/>
 <result pre="of the outbreakInt. J. Infect. Dis.20209221421710.1016/j.ijid.2020.01.05032007643 40.ZhaiP.DingY.WuX.LongJ.ZhongY.LiY.The epidemiology, diagnosis and" exact="treatment" post="of COVID-19Int J. Antimicrob Agents20205510595510.1016/j.ijantimicag.2020.10595532234468 41.CascellaM.RajnikM.CuomoA.DulebohnS.C.Di NapoliR.Features, Evaluation and"/>
 <result pre="J. Med.20193812293230310.1056/NEJMoa191099331774950 62.VincentM.J.BergeronE.BenjannetS.EricksonB.R.RollinP.E.KsiazekT.G.SeidahN.G.NicholS.T.Chloroquine is a potent inhibitor of SARS coronavirus" exact="infection" post="and spreadVirol. J.200526910.1186/1743-422X-2-6916115318 63.Ruiz-IrastorzaG.Ramos-CasalsM.Brito-ZeronP.KhamashtaM.A.Clinical efficacy and side effects of"/>
 <result pre="by peripheral blood mononuclear cellsJ. Rheumatol.19972455609002011 65.StockmanL.J.BellamyR.GarnerP.SARS: Systematic review of" exact="treatment" post="effectsPLoS Med.20063e34310.1371/journal.pmed.003034316968120 66.ChuC.M.ChengV.C.HungI.F.WongM.M.ChanK.H.ChanK.S.KaoR.Y.PoonL.L.WongC.L.GuanY.et al.Group, HUSS. Role of lopinavir/ritonavir in"/>
 <result pre="effectsPLoS Med.20063e34310.1371/journal.pmed.003034316968120 66.ChuC.M.ChengV.C.HungI.F.WongM.M.ChanK.H.ChanK.S.KaoR.Y.PoonL.L.WongC.L.GuanY.et al.Group, HUSS. Role of lopinavir/ritonavir in the" exact="treatment" post="of SARS: Initial virological and clinical findingsThorax20045925225610.1136/thorax.2003.01265814985565 67.DelangL.AbdelnabiR.NeytsJ.Favipiravir as"/>
</results>
